EGFR and central nervous system cancer: In contrast, poor-prognosis low-grade gliomas (lacking IDH mutation) and primary glioblastomas (GBMs) are characterized by EGFR amplification along with deletions/mutations of the phosphatase and tensin homolog tumor suppressor gene (PTEN) [29,31].